
Pyxis Oncology, Inc. – NASDAQ:PYXS
Pyxis Oncology stock price today
Pyxis Oncology stock price monthly change
Pyxis Oncology stock price quarterly change
Pyxis Oncology stock price yearly change
Pyxis Oncology key metrics
Market Cap | 94.84M |
Enterprise value | N/A |
P/E | -1.1 |
EV/Sales | N/A |
EV/EBITDA | 0.19 |
Price/Sales | N/A |
Price/Book | 0.78 |
PEG ratio | -0.01 |
EPS | -1.38 |
Revenue | N/A |
EBITDA | -64.44M |
Income | -57.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePyxis Oncology stock price history
Pyxis Oncology stock forecast
Pyxis Oncology financial statements
Jun 2023 | 0 | -15.90M | |
---|---|---|---|
Sep 2023 | 0 | -23.04M | |
Dec 2023 | 3.42M | -15.59M | -456.05% |
Mar 2024 | 16.14M | -3.25M | -20.17% |
Sep 2025 | 125K | -13.38M | -10709.66% |
---|---|---|---|
Oct 2025 | 125K | -18.42M | -14742.59% |
Dec 2025 | 0 | -15.16M | |
Dec 2025 | 125K | -17.79M | -14234.62% |
Analysts Price target
Financials & Ratios estimates
2024-03-21 | -0.49 | -0.33 |
---|---|---|
2024-05-14 | -0.27 | -0.06 |
Jun 2023 | 175230000 | 29.95M | 17.09% |
---|---|---|---|
Sep 2023 | 186692000 | 48.74M | 26.11% |
Dec 2023 | 173726000 | 48.02M | 27.64% |
Mar 2024 | 220220000 | 36.06M | 16.38% |
Jun 2023 | -11.03M | -22.25M | 6.12M |
---|---|---|---|
Sep 2023 | -17.58M | 6.57M | -171K |
Dec 2023 | -15.25M | 10.22M | -25K |
Mar 2024 | -20.71M | -18.49M | 57.51M |
Pyxis Oncology alternative data
Aug 2023 | 73 |
---|---|
Sep 2023 | 72 |
Oct 2023 | 72 |
Nov 2023 | 72 |
Dec 2023 | 67 |
Jan 2024 | 67 |
Feb 2024 | 67 |
Mar 2024 | 50 |
Apr 2024 | 50 |
May 2024 | 50 |
Jun 2024 | 51 |
Jul 2024 | 51 |
Pyxis Oncology other data
Period | Buy | Sel |
---|---|---|
Nov 2024 | 88850 | 0 |
Insider | Compensation |
---|---|
Dr. Ronald Herbst Ph.D. (1961) Chief Scientific Officer | $468,600 |
-
What's the price of Pyxis Oncology stock today?
One share of Pyxis Oncology stock can currently be purchased for approximately $1.2.
-
When is Pyxis Oncology's next earnings date?
Unfortunately, Pyxis Oncology's (PYXS) next earnings date is currently unknown.
-
Does Pyxis Oncology pay dividends?
No, Pyxis Oncology does not pay dividends.
-
How much money does Pyxis Oncology make?
Pyxis Oncology has a market capitalization of 94.84M. Pyxis Oncology made a loss 73.79M US dollars in net income (profit) last year or -$0.06 on an earnings per share basis.
-
What is Pyxis Oncology's stock symbol?
Pyxis Oncology, Inc. is traded on the NASDAQ under the ticker symbol "PYXS".
-
What is Pyxis Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pyxis Oncology?
Shares of Pyxis Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Pyxis Oncology's key executives?
Pyxis Oncology's management team includes the following people:
- Dr. Ronald Herbst Ph.D. Chief Scientific Officer(age: 64, pay: $468,600)
-
How many employees does Pyxis Oncology have?
As Jul 2024, Pyxis Oncology employs 51 workers, which is 2% more then previous quarter.
-
When Pyxis Oncology went public?
Pyxis Oncology, Inc. is publicly traded company for more then 3 years since IPO on 8 Oct 2021.
-
What is Pyxis Oncology's official website?
The official website for Pyxis Oncology is pyxisoncology.com.
-
Where are Pyxis Oncology's headquarters?
Pyxis Oncology is headquartered at 35 Cambridgepark Drive, Cambridge, MA.
-
How can i contact Pyxis Oncology?
Pyxis Oncology's mailing address is 35 Cambridgepark Drive, Cambridge, MA and company can be reached via phone at +61 72219059.
Pyxis Oncology company profile:

Pyxis Oncology, Inc.
pyxisoncology.comNASDAQ
54
Biotechnology
Healthcare
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02140
CIK: 0001782223
ISIN: US7473241013
CUSIP: 747324101